Black Diamond Therapeutics to Present Phase 2 Silevertinib Results for EGFR-Mutant NSCLC
核心洞察
Black Diamond Therapeutics will host a webcast on December 3, 2025, to present Phase 2 clinical trial results for silevertinib (搜索), a brain-penetrant fourth-generation EGFR (搜索) inhibitor.
Silevertinib (搜索) is being evaluated in a Phase 2 trial for non-small cell lung cancer patients with EGFR (搜索) mutations and glioblastoma.
The company's MasterKey therapy approach is designed to target families of oncogenic mutations while overcoming resistance and minimizing toxicities.
Black Diamond Therapeutics will present Phase 2 clinical trial results for silevertinib (搜索), its brain-penetrant fourth-generation epidermal growth factor receptor (EGFR (搜索)) inhibitor, during a webcast scheduled for December 3, 2025, at 8:00am ET. The clinical-stage oncology company is advancing the drug for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma.
MasterKey Therapy Platform
Black Diamond Therapeutics has developed what it calls MasterKey therapies, which are designed to target families of oncogenic mutations in cancer patients. According to the company, these therapies are engineered to address a broad spectrum of genetically defined tumors while overcoming resistance mechanisms and minimizing wild-type mediated toxicities. A key feature of the platform is its brain-penetrant design, specifically developed to treat central nervous system disease.
Silevertinib Development Program
The company is currently advancing a Phase 2 NSCLC trial of silevertinib (搜索), positioning it as a fourth-generation EGFR (搜索) MasterKey inhibitor. The drug targets EGFR-mutant NSCLC and glioblastoma, representing a potential advancement in treating these challenging cancer types that often involve central nervous system complications.
The upcoming webcast will not only present the Phase 2 clinical trial results but also provide a comprehensive program update on silevertinib (搜索)'s development trajectory.
Webcast Details
The presentation will be accessible through the "Events and Presentations" section on the Investors page of Black Diamond's website at www.blackdiamondtherapeutics.com. A replay of the webcast will be made available following the completion of the live event, allowing stakeholders to review the clinical data and program updates at their convenience.